HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has d ...

Core Viewpoint - Johnson Fistel, LLP is investigating Paycor HCM, Inc. for potential violations of securities laws related to misrepresentation or failure to disclose material information affecting investors [1]. Group 1: Investigation Details - The investigation focuses on the losses suffered by investors and the possibility of recovering these losses under federal securities laws [1]. - Shareholders who purchased Paycor HCM securities and experienced losses are encouraged to join the investigation [2]. Group 2: Whistleblower Information - Individuals with nonpublic information about Paycor HCM are advised to consider assisting the investigation or utilizing the SEC Whistleblower program, which may offer rewards up to 30% of any successful recovery [3]. Group 3: About the Law Firm - Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado, representing both individual and institutional investors in securities class action lawsuits [4].

Core Insights - HUTCHMED is set to present new data from the ESLIM-01 Phase III trial of sovleplenib and other investigator-initiated studies at major upcoming medical conferences, including the ASH Annual Meeting and ESMO Asia Congress in December 2024 [1][4] Group 1: ESLIM-01 Phase III Trial Data - Long-term safety and efficacy data from the ESLIM-01 Phase III study of sovleplenib in adult patients with chronic primary immune thrombocytopenia (ITP) will be reported, with 179 patients treated as of January 31, 2024 [2][3] - The overall response rate for patients was 81% (145/179), with a durable response rate of 51.4% and a long-term durable response rate of 59.8% [3] Group 2: Upcoming Presentations - The ASH Annual Meeting will feature a follow-on sub-study demonstrating the effectiveness of long-term treatment with sovleplenib in maintaining platelet counts in adults with chronic primary ITP [2][3] - The ESMO Asia Congress will include studies on fruquintinib combined with serplulimab for advanced non-clear cell renal cell carcinoma and other cancer treatments [4][6] Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, employing approximately 5,000 personnel [7]

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it will receive a US$20 million milestone payment from its partner Takeda (TSE:​4502/​NYSE:​TAK), triggered by reaching over US$200 million in sales of FRUZAQLA® (fruquintinib) for metastatic colorectal cancer (“CRC”). CRC is the second most common cause of cancer-related deaths in the US. There are approximately 840,000 new cases of CRC each ...

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that add ...

— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces positive high-level results from the SAVANNAH Phase II trial that showed TAGRISSO® (osimertinib) plus ORPATHYS ...

Shares of HUTCHMED (China) Ltd (HCM, Financial) surged 2.90% in mid-day trading on Oct 2. The stock reached an intraday high of $21.10, before settling at $20.58, up from its previous close of $20.00. This places HCM 6.11% below its 52-week high of $21.92 and 72.44% above its 52-week low of $11.93. Trading volume was 210,051 shares, 216.8% of the average daily volume of 96,867. Wall Street Analysts Forecast Based on the one-year price targets offered by 12 analysts, the average target price for HUTCHMED (Ch ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population  Study design intended to enable supplemental new drug application (sNDA) with a broad label in both obstructive and non-obstructive HCM THE WOODLANDS, Texas, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will unveil study design details of SONATA-HCM, the company’s Phase 3 clinica ...

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its partner Takeda (TSE:​4502/​NYSE:​TAK) has received approval from the Japanese Ministry of Health, Labour and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place in Barcelona, Spain. Results from the FLOWERS study, a prospective, two-arm, randomized, mul ...